DERMATA THERAPEUTICS, INC. Research and Development Expense
DERMATA THERAPEUTICS, INC. (DRMA) reported Research and Development Expense of $212.56 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- DERMATA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $212.56K, a 65.60% decline year-over-year.
- DERMATA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $383.72K, a 70.05% decline year-over-year.
- DERMATA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $526.62K, a 75.98% decline year-over-year.
- DERMATA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $504.39K, a 79.00% decline year-over-year.
- DERMATA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $2.93M, a 64.28% decline from fiscal 2024.
- DERMATA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $8.20M, a 101.58% increase from fiscal 2023.
- DERMATA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $4.07M, a 27.98% decline from fiscal 2022.
- DERMATA THERAPEUTICS, INC. research and development expense for fiscal 2022 was $5.65M, a 63.36% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $212.56K 10-Q · filed 2026-08-11 | $596.29K 10-Q · filed 2026-08-11 | $1.12M derived: sum of 3 quarters · filed 2026-08-11 | $1.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $383.72K 10-Q · filed 2026-05-13 | $910.34K derived: sum of 2 quarters · filed 2026-05-13 | $1.41M derived: sum of 3 quarters · filed 2026-05-13 | $2.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $526.62K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.03M derived: sum of 2 quarters · filed 2026-03-26 | $1.65M derived: sum of 3 quarters · filed 2026-08-11 | $2.93M 10-K · filed 2026-03-26 |
| 2025-09-30 | $504.39K 10-Q · filed 2025-11-14 | $1.12M derived: sum of 2 quarters · filed 2026-08-11 | $2.40M 10-Q · filed 2025-11-14 | $4.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $617.84K 10-Q · filed 2026-08-11 | $1.90M 10-Q · filed 2026-08-11 | $4.09M derived: sum of 3 quarters · filed 2026-08-11 | $6.49M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.28M 10-Q · filed 2026-05-13 | $3.47M derived: sum of 2 quarters · filed 2026-05-13 | $5.87M derived: sum of 3 quarters · filed 2026-05-13 | $7.88M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.59M derived: sum of 2 quarters · filed 2026-03-26 | $6.60M derived: sum of 3 quarters · filed 2026-03-26 | $8.20M 10-K · filed 2026-03-26 |
| 2024-09-30 | $2.40M 10-Q · filed 2025-11-14 | $4.41M derived: sum of 2 quarters · filed 2025-11-14 | $6.01M 10-Q · filed 2025-11-14 | $7.15M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.01M 10-Q · filed 2025-08-13 | $3.61M 10-Q · filed 2025-08-13 | $4.75M derived: sum of 3 quarters · filed 2025-08-13 | $5.65M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.60M 10-Q · filed 2025-05-14 | $2.74M derived: sum of 2 quarters · filed 2025-05-14 | $3.64M derived: sum of 3 quarters · filed 2025-05-14 | $4.48M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.04M derived: sum of 2 quarters · filed 2025-03-17 | $2.88M derived: sum of 3 quarters · filed 2025-03-17 | $4.07M 10-K · filed 2025-03-17 |
| 2023-09-30 | $902.98K 10-Q · filed 2024-11-13 | $1.74M derived: sum of 2 quarters · filed 2024-11-13 | $2.93M 10-Q · filed 2024-11-13 | $3.82M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $838.93K 10-Q · filed 2024-08-07 | $2.03M 10-Q · filed 2024-08-07 | $2.92M derived: sum of 3 quarters · filed 2024-08-07 | $4.47M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $1.19M 10-Q · filed 2024-05-15 | $2.08M derived: sum of 2 quarters · filed 2024-05-15 | $3.64M derived: sum of 3 quarters · filed 2024-05-15 | $5.25M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $889.36K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.44M derived: sum of 2 quarters · filed 2024-03-21 | $4.06M derived: sum of 3 quarters · filed 2024-03-21 | $5.65M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.55M 10-Q · filed 2023-11-09 | $3.17M derived: sum of 2 quarters · filed 2023-11-09 | $4.76M 10-Q · filed 2023-11-09 | $5.87M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.61M 10-Q · filed 2023-08-10 | $3.21M 10-Q · filed 2023-08-10 | $4.32M derived: sum of 3 quarters · filed 2023-08-10 | $5.12M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.60M 10-Q · filed 2023-05-11 | $2.71M derived: sum of 2 quarters · filed 2023-05-11 | $3.51M derived: sum of 3 quarters · filed 2023-05-11 | $4.37M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $1.91M derived: sum of 2 quarters · filed 2023-02-21 | $2.78M derived: sum of 3 quarters · filed 2023-02-21 | $3.46M 10-K · filed 2023-02-21 |
| 2021-09-30 | $799.78K 10-Q · filed 2022-11-10 | $1.67M derived: sum of 2 quarters · filed 2022-11-10 | $2.35M 10-Q · filed 2022-11-10 | $2.46M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $867.20K 10-Q · filed 2022-08-15 | $1.55M 10-Q · filed 2022-08-15 | $1.66M derived: sum of 3 quarters · filed 2022-08-15 | $1.78M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $680.59K 10-Q · filed 2022-05-16 | $794.89K derived: sum of 2 quarters · filed 2022-05-16 | $915.35K derived: sum of 3 quarters · filed 2022-05-16 | $1.33M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $114.30K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $234.76K derived: sum of 2 quarters · filed 2022-03-28 | $646.71K derived: sum of 3 quarters · filed 2022-03-28 | $1.61M 10-K · filed 2022-03-28 |
| 2020-09-30 | $120.47K 10-Q · filed 2021-11-15 | $532.41K derived: sum of 2 quarters · filed 2021-11-15 | $1.49M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $411.95K 10-Q · filed 2021-09-27 | $1.37M 10-Q · filed 2021-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |